Alkermes (ALKS) Cash from Financing Activities (2010 - 2026)
Alkermes (ALKS) posted quarterly Cash from Financing Activities of $17.2 million for Q2 2026, up 4148.15% year-over-year from $405000.0 in Q2 2025, and down 98.83% quarter-over-quarter from $1.5 billion in Q1 2026.
Alkermes (ALKS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Cash from Financing Activities for 17 consecutive years, with $17.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 4148.15% year-over-year to $17.2 million; the TTM figure through Jun 2026 stood at $1.5 billion (up 483.77% YoY), while the FY2025 annual figure was $12.4 million, up 102.51% from the prior year.
- Cash from Financing Activities eased to $17.2 million in Q2 2026 per ALKS's latest filing, from $1.5 billion in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $1.5 billion in Q1 2026 and bottomed at -$281.7 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged $39.9 million across 5 years, with a median of $51500.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 101928.41% — and 2026, when it jumped 197292.1%.
- Alkermes' Cash from Financing Activities stood at -$271000.0 in 2022, then plunged by 101928.41% to -$276.5 million in 2023, then decreased by 1.87% to -$281.7 million in 2024, then jumped by 103.87% to $10.9 million in 2025, then soared by 57.67% to $17.2 million in 2026.
- Business Quant data shows ALKS's Cash from Financing Activities at $17.2 million in Q2 2026, $1.5 billion in Q1 2026, and $10.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.21 Mn |
| Jun 30, 2026 | 17.21 Mn |
| Mar 31, 2026 | 1.47 Bn |
| Mar 31, 2026 | 1.47 Bn |
| Dec 31, 2025 | 10.91 Mn |
| Dec 31, 2025 | 10.91 Mn |
| Sep 30, 2025 | 315,000.00 |
| Sep 30, 2025 | 315,000.00 |
| Jun 30, 2025 | 405,000.00 |
| Jun 30, 2025 | 405,000.00 |
| Mar 31, 2025 | 747,000.00 |
| Mar 31, 2025 | 747,000.00 |
| Dec 31, 2024 | -281.67 Mn |
| Dec 31, 2024 | -281.67 Mn |
| Sep 30, 2024 | -111.11 Mn |
| Sep 30, 2024 | -111.11 Mn |
| Jun 30, 2024 | -83.48 Mn |
| Jun 30, 2024 | -83.48 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Mar 31, 2024 | -17.87 Mn |